Skip to content

Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)

Endoscopic Papillary Short Duration Large Balloon Dilatation for Removal of Large Bile Duct Stones: a Prospective Multicenter Study of Short and Long-term Adverse Events

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05061680
Acronym
SHODBADI
Enrollment
600
Registered
2021-09-29
Start date
2021-04-05
Completion date
2026-12-31
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bleeding, Cholangitis, Pancreatitis, Acute

Brief summary

ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla. The investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.

Detailed description

This study is planned as a multicenter Scandinavian prospective study including all the patients \>18 years with \>10mm diameter common bile duct stones visible in cholangiogram. Before ERCP all patient will be informed about this trial, and if they agree to participate this study, they need to give a written informed consent. The endoscopists will decide whether the first step will be large EST and stone extraction or small EST and dilatation. If simple EST does not success, the dilatation will remain as a rescue method. The diameter of dilatation balloon cannot exceed the diameter of common bile duct above the papilla. Cholangiogram is followed when papilla is dilated and the dilatation will be ended when the waist of the papilla disappears. The duration of the dilatation measured, but it does not define the ending of dilatation. All adverse events will be recorded one month and a year after the procedure. Classification of the patients: 1. EST and stone extraction 2. EPLBD when EST and stone extraction did not succeed 3. Short EST and EPLBD The investigators will collect the information of adverse events such as bleeding, pancreatitis, cholangitis with patient questionnaire as well as from the patient records one month and a year after the procedure

Interventions

DEVICEendoscopic short duration papillary large balloon dilation

During the large balloon papillary dilation investigators follow the cholangiogram and stop the dilatation as soon as the disappearance of the waist of the papilla is noticed.

Sponsors

Helsinki University Central Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* Age \>18 years * Common bile duct stone \>10mm diameter

Exclusion criteria

* Altered anatomy after surgery (B II, Roux-en-Y reconstruction) * Common bile duct cysts * Acute pancreatitis * Distal common bile duct stricture or tumor * Coagulation disorders * Ongoing coagulation medication * Pregnancy * Inability to give an informed consent

Design outcomes

Primary

MeasureTime frameDescription
Rate of bleeding30 daysneed for additional intervention or need for blood transfusion and hemoglobin drop more than 2 gm/dL
Rate of pancreatitis30 daysPlasma amylase rises \>3 times the upper limit and newly developed stomach ace more than 24h
Rate of cholangitis30 daysFever \>38

Countries

Finland

Contacts

Primary ContactMia Rainio, MD, PhD
mia.rainio@hus.fi+358505833060
Backup ContactLeena Kylänpää, MD, PhD
leena.kylanpaa@hus.fi+35894711

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026